 Christopher Raeburn
Concepts (339)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 12 | 2024 | 271 | 1.340 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 85 | 0.930 |
Why?
| | Pancreatic Neoplasms | 3 | 2022 | 721 | 0.660 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2022 | 34 | 0.600 |
Why?
| | Intercellular Adhesion Molecule-1 | 5 | 2011 | 147 | 0.460 |
Why?
| | Ischemic Preconditioning | 2 | 2004 | 28 | 0.420 |
Why?
| | Diiodothyronines | 1 | 2011 | 3 | 0.380 |
Why?
| | Myocardial Ischemia | 2 | 2011 | 239 | 0.370 |
Why?
| | Propionates | 1 | 2011 | 34 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2010 | 1128 | 0.360 |
Why?
| | Heart | 3 | 2004 | 613 | 0.350 |
Why?
| | Delirium | 4 | 2014 | 66 | 0.340 |
Why?
| | Myocarditis | 1 | 2011 | 93 | 0.340 |
Why?
| | Technetium Tc 99m Sestamibi | 3 | 2015 | 12 | 0.340 |
Why?
| | Parathyroid Glands | 3 | 2015 | 10 | 0.340 |
Why?
| | Ischemic Preconditioning, Myocardial | 4 | 2010 | 29 | 0.340 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 191 | 0.330 |
Why?
| | Surgical Procedures, Operative | 2 | 2002 | 206 | 0.330 |
Why?
| | Lipopolysaccharides | 5 | 2002 | 813 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2016 | 193 | 0.310 |
Why?
| | Thyroidectomy | 5 | 2018 | 62 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 179 | 0.300 |
Why?
| | Adrenocortical Carcinoma | 2 | 2018 | 47 | 0.290 |
Why?
| | Postoperative Complications | 8 | 2023 | 2122 | 0.280 |
Why?
| | Shock, Hemorrhagic | 3 | 2004 | 152 | 0.280 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 350 | 0.270 |
Why?
| | Myocardial Infarction | 2 | 2011 | 932 | 0.260 |
Why?
| | Radionuclide Imaging | 3 | 2013 | 115 | 0.260 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2002 | 35 | 0.250 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2003 | 140 | 0.250 |
Why?
| | Neutrophils | 6 | 2011 | 1089 | 0.240 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2021 | 81 | 0.240 |
Why?
| | Biomarkers, Tumor | 4 | 2021 | 1032 | 0.230 |
Why?
| | Hypocalcemia | 2 | 2015 | 30 | 0.230 |
Why?
| | Iodine Radioisotopes | 4 | 2022 | 126 | 0.220 |
Why?
| | Drosophila Proteins | 2 | 2002 | 164 | 0.220 |
Why?
| | Carcinoma, Neuroendocrine | 3 | 2022 | 29 | 0.220 |
Why?
| | Antigens, CD | 2 | 2003 | 440 | 0.220 |
Why?
| | Thyroid Nodule | 1 | 2024 | 45 | 0.220 |
Why?
| | Membrane Glycoproteins | 2 | 2002 | 429 | 0.210 |
Why?
| | Endotoxemia | 2 | 2010 | 86 | 0.210 |
Why?
| | Osteitis Fibrosa Cystica | 1 | 2002 | 1 | 0.210 |
Why?
| | Thyroxine | 1 | 2023 | 57 | 0.210 |
Why?
| | Thoracic Surgery | 1 | 2004 | 106 | 0.210 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 12 | 0.210 |
Why?
| | Pheochromocytoma | 2 | 2021 | 54 | 0.210 |
Why?
| | Hypothyroidism | 1 | 2023 | 65 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2022 | 787 | 0.210 |
Why?
| | Myocardium | 5 | 2011 | 911 | 0.200 |
Why?
| | Iodine | 1 | 2022 | 18 | 0.200 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 94 | 0.200 |
Why?
| | Chemokines | 4 | 2011 | 215 | 0.190 |
Why?
| | Interleukin-18 | 1 | 2002 | 217 | 0.180 |
Why?
| | Tryptophan | 2 | 2014 | 136 | 0.180 |
Why?
| | Adrenalectomy | 1 | 2000 | 59 | 0.180 |
Why?
| | Prognosis | 4 | 2022 | 3315 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 145 | 0.180 |
Why?
| | Humans | 42 | 2024 | 114045 | 0.180 |
Why?
| | Paraganglioma | 1 | 2021 | 46 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 164 | 0.170 |
Why?
| | Abdominal Injuries | 1 | 2000 | 107 | 0.160 |
Why?
| | Stress, Physiological | 1 | 2002 | 379 | 0.160 |
Why?
| | Pancreatectomy | 1 | 2000 | 167 | 0.160 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.160 |
Why?
| | Trans-Activators | 1 | 2021 | 366 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1145 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 32 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 228 | 0.150 |
Why?
| | Animals | 17 | 2021 | 31565 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1356 | 0.150 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 30 | 0.140 |
Why?
| | Mice, Inbred C57BL | 6 | 2011 | 4680 | 0.140 |
Why?
| | Mice | 13 | 2021 | 14843 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 48 | 0.140 |
Why?
| | Carcinoma | 1 | 2018 | 198 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 784 | 0.140 |
Why?
| | Medical Oncology | 1 | 2018 | 229 | 0.140 |
Why?
| | Cytokines | 2 | 2015 | 1824 | 0.130 |
Why?
| | Adrenal Glands | 1 | 2016 | 66 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 393 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 75 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 111 | 0.120 |
Why?
| | Virus Latency | 1 | 2016 | 80 | 0.120 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 3 | 2004 | 73 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2015 | 89 | 0.120 |
Why?
| | Islets of Langerhans | 1 | 2000 | 728 | 0.120 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2014 | 38 | 0.110 |
Why?
| | Male | 24 | 2017 | 55396 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 349 | 0.110 |
Why?
| | Middle Aged | 16 | 2019 | 26605 | 0.110 |
Why?
| | Elective Surgical Procedures | 2 | 2014 | 150 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2016 | 686 | 0.110 |
Why?
| | Carotid Artery Injuries | 2 | 2004 | 44 | 0.110 |
Why?
| | Tunica Intima | 2 | 2004 | 78 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2015 | 337 | 0.110 |
Why?
| | Subtraction Technique | 1 | 2013 | 24 | 0.110 |
Why?
| | Chemokine CCL2 | 2 | 2011 | 104 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2015 | 684 | 0.100 |
Why?
| | Mice, Knockout | 6 | 2004 | 2562 | 0.100 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 2700 | 0.100 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 377 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2024 | 1690 | 0.100 |
Why?
| | Carcinoma, Papillary | 1 | 2012 | 74 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 158 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2021 | 2173 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 53 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 158 | 0.090 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 65 | 0.090 |
Why?
| | Antibodies | 2 | 2002 | 365 | 0.090 |
Why?
| | Aged | 12 | 2019 | 18969 | 0.090 |
Why?
| | Vascular Surgical Procedures | 2 | 2004 | 260 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 61 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1089 | 0.080 |
Why?
| | Extracellular Space | 1 | 2010 | 116 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2011 | 3498 | 0.080 |
Why?
| | Endotoxins | 1 | 2010 | 211 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1016 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 926 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 252 | 0.080 |
Why?
| | Intestinal Perforation | 1 | 2008 | 39 | 0.080 |
Why?
| | Duodenum | 1 | 2008 | 62 | 0.080 |
Why?
| | Acute Disease | 1 | 2011 | 907 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2010 | 321 | 0.070 |
Why?
| | Pancreatic Ducts | 1 | 2008 | 69 | 0.070 |
Why?
| | Female | 16 | 2021 | 59324 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 68 | 0.070 |
Why?
| | Mutation | 4 | 2021 | 3338 | 0.070 |
Why?
| | Macrophages | 2 | 2011 | 1259 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2011 | 673 | 0.070 |
Why?
| | Software | 1 | 2011 | 526 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2349 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 873 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2008 | 201 | 0.070 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 180 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2272 | 0.070 |
Why?
| | Carotid Arteries | 2 | 2004 | 180 | 0.060 |
Why?
| | Hyperplasia | 2 | 2004 | 163 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 2 | 2017 | 65 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2002 | 167 | 0.060 |
Why?
| | Signal Transduction | 3 | 2016 | 4501 | 0.060 |
Why?
| | Preoperative Care | 2 | 2011 | 319 | 0.060 |
Why?
| | Transplantation | 1 | 2004 | 23 | 0.060 |
Why?
| | Vasculitis | 1 | 2004 | 65 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 850 | 0.060 |
Why?
| | Insulinoma | 1 | 2003 | 29 | 0.050 |
Why?
| | Risk Assessment | 3 | 2015 | 2958 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1162 | 0.050 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2004 | 146 | 0.050 |
Why?
| | Time Factors | 4 | 2015 | 6077 | 0.050 |
Why?
| | Risk Factors | 5 | 2012 | 8614 | 0.050 |
Why?
| | Computers | 1 | 2023 | 60 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2018 | 9049 | 0.050 |
Why?
| | Parathyroidectomy | 1 | 2002 | 7 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 13 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2004 | 150 | 0.050 |
Why?
| | Thyrotropin | 1 | 2023 | 100 | 0.050 |
Why?
| | Collateral Circulation | 1 | 2002 | 18 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 438 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 521 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 274 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2004 | 293 | 0.050 |
Why?
| | Vinblastine | 1 | 2002 | 63 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2002 | 72 | 0.050 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 10 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 132 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2002 | 33 | 0.050 |
Why?
| | Internship and Residency | 1 | 2011 | 920 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1624 | 0.050 |
Why?
| | Vasopressins | 1 | 2002 | 56 | 0.050 |
Why?
| | Coronary Disease | 1 | 2004 | 348 | 0.050 |
Why?
| | Hemostatics | 1 | 2002 | 44 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 303 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2002 | 396 | 0.050 |
Why?
| | Lung | 3 | 2002 | 3521 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 19 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 181 | 0.050 |
Why?
| | Adenoma | 1 | 2002 | 187 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 57 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2003 | 362 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1003 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 635 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 315 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2001 | 174 | 0.040 |
Why?
| | Laparotomy | 1 | 2000 | 101 | 0.040 |
Why?
| | Interleukins | 1 | 2002 | 236 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2001 | 126 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 203 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2001 | 280 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 146 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 845 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 3 | 2010 | 285 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 628 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2001 | 159 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 271 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2016 | 6306 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 435 | 0.040 |
Why?
| | Military Medicine | 1 | 2000 | 92 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 30 | 0.040 |
Why?
| | Graft Rejection | 1 | 2002 | 511 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 310 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 248 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 5 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 5 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 695 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 227 | 0.040 |
Why?
| | Homeostasis | 1 | 2002 | 570 | 0.040 |
Why?
| | Reoperation | 1 | 2000 | 513 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2018 | 85 | 0.040 |
Why?
| | NF-kappa B | 3 | 2010 | 636 | 0.040 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2002 | 284 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 965 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.040 |
Why?
| | Immunoblotting | 1 | 2018 | 282 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2000 | 735 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 414 | 0.040 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 14 | 0.040 |
Why?
| | Adult | 6 | 2016 | 30375 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 314 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2015 | 3003 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 131 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2023 | 12521 | 0.030 |
Why?
| | Frozen Sections | 1 | 1996 | 24 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 636 | 0.030 |
Why?
| | Prospective Studies | 3 | 2015 | 6195 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2002 | 720 | 0.030 |
Why?
| | Laparoscopy | 1 | 2000 | 395 | 0.030 |
Why?
| | Tracheostomy | 1 | 1997 | 97 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 723 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 84 | 0.030 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2016 | 19 | 0.030 |
Why?
| | Cricoid Cartilage | 1 | 2015 | 15 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2371 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 75 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 93 | 0.030 |
Why?
| | Herpes Simplex | 1 | 2016 | 87 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 135 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2537 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 26 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 655 | 0.030 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 76 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 132 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 607 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 188 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 549 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 124 | 0.030 |
Why?
| | Niacinamide | 1 | 2014 | 63 | 0.030 |
Why?
| | Paclitaxel | 1 | 2015 | 190 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 67 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 81 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 241 | 0.030 |
Why?
| | Doxorubicin | 1 | 2015 | 286 | 0.030 |
Why?
| | Melatonin | 1 | 2014 | 106 | 0.030 |
Why?
| | Incidence | 2 | 2011 | 2314 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2004 | 34 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 3 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1331 | 0.030 |
Why?
| | Neck Dissection | 1 | 2012 | 10 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 990 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2014 | 241 | 0.030 |
Why?
| | Postoperative Care | 1 | 2014 | 223 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2004 | 398 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 383 | 0.030 |
Why?
| | Inflammation | 1 | 2003 | 2464 | 0.030 |
Why?
| | Preoperative Period | 1 | 2012 | 102 | 0.030 |
Why?
| | Serotonin | 1 | 2014 | 292 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 925 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 419 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 924 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 275 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2002 | 1726 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2505 | 0.020 |
Why?
| | Intraoperative Period | 2 | 2003 | 51 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 84 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 768 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 224 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 10444 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1656 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2014 | 614 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2010 | 60 | 0.020 |
Why?
| | Workload | 1 | 2011 | 131 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2012 | 415 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2011 | 175 | 0.020 |
Why?
| | Safety | 1 | 2011 | 298 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 959 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1422 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2086 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 96 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1075 | 0.020 |
Why?
| | Bile Ducts | 1 | 2008 | 68 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1036 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1218 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 277 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1206 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1829 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 918 | 0.020 |
Why?
| | Cell Movement | 2 | 2001 | 863 | 0.020 |
Why?
| | Patient Readmission | 1 | 2012 | 607 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 492 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 2784 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 517 | 0.020 |
Why?
| | Protein Binding | 1 | 2010 | 1888 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1638 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 138 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2885 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2764 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1350 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 82 | 0.010 |
Why?
| | United States | 1 | 2018 | 12137 | 0.010 |
Why?
| | Monokines | 1 | 2002 | 24 | 0.010 |
Why?
| | Chemokine CXCL2 | 1 | 2002 | 41 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 161 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 242 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 61 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 49 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 249 | 0.010 |
Why?
| | Lymphokines | 1 | 2001 | 110 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2002 | 110 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 4883 | 0.010 |
Why?
| | Postoperative Period | 1 | 2002 | 288 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 223 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4392 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 787 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 580 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 4595 | 0.010 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2002 | 222 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 372 | 0.010 |
Why?
| | Colorado | 1 | 2008 | 4090 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 496 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 723 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 167 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1417 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 196 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 1996 | 180 | 0.010 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1997 | 154 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2001 | 611 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2550 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 544 | 0.010 |
Why?
| | Adolescent | 1 | 1997 | 17800 | 0.000 |
Why?
|
|
Raeburn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|